Do progesterone-only contraceptives affect von Willebrand factor testing results?

Progesterone-Only Contraceptives Do Not Significantly Affect Von Willebrand Factor Testing

Progesterone-only contraceptives (POCs) do not meaningfully alter von Willebrand factor (VWF) or Factor VIII levels and should not interfere with VWD testing. You can proceed with diagnostic testing while patients remain on POCs without requiring discontinuation.

Key Evidence on Hormonal Effects

The critical distinction is between combined hormonal contraceptives (which contain estrogen) and progesterone-only methods:

Combined Hormonal Contraceptives (Estrogen-Containing)

• Do increase VWF and Factor VIII levels 1
• Estrogen administration is specifically noted as a condition that may falsely elevate VWF and FVIII levels 1
• However, modern low-dose formulations appear to have minimal impact on VWD diagnosis 2

Progesterone-Only Contraceptives

• Do NOT significantly affect hemostatic parameters when used in small doses 3
• Microdose progestin-based oral contraceptives (desogestrel, levonorgestrel) and levonorgestrel IUDs show no significant increase in VTE risk or alteration of coagulation factors 3
• These results were expected because progestins do not affect hemostatic parameters when used in small doses 3

Clinical Implications for Testing

You can test for VWD while patients are on progesterone-only contraceptives because:

1. No interference with VWF levels: POCs do not alter VWF antigen, VWF activity (ristocetin cofactor), or Factor VIII levels in clinically meaningful ways

2. Avoids bleeding risk: Requiring patients to discontinue POCs risks recurrent severe menorrhagia, potentially leading to hospital admission and transfusion 2

3. Practical approach: The 2025 VWD diagnostic guidelines 4 note that VWF levels are affected by estrogens (oral contraceptive pill) but make no specific mention of progesterone-only methods requiring discontinuation

Important Caveats

Exception: Depot Medroxyprogesterone Acetate (DMPA)

• DMPA may carry higher thrombotic risk than other POCs 5, 3
• Limited data suggest DMPA may increase VTE risk (RR 2.67) 5
• However, this relates to thrombosis risk, not diagnostic interference with VWF testing
• Two studies found increased odds of VTE with DMPA use 6, 7

Timing Considerations

• Avoid testing during acute heavy menstrual bleeding when possible 8
• VWF levels increase with stress and acute bleeding, potentially masking VWD diagnosis
• 69% of patients with VWD had low VWF levels during acute HMB, but median levels were higher during acute bleeding than at follow-up 8
• Test after bleeding resolution and anemia correction for most accurate results 8

Practical Testing Algorithm

For patients on progesterone-only contraceptives:

1. Continue POC without interruption
2. Schedule testing when patient is NOT actively bleeding
3. Ensure atraumatic blood draw to avoid stress-related VWF elevation 1
4. Consider blood type O status (VWF levels ~25-30% lower) 4, 1
5. If initial results borderline, repeat testing may be needed

For patients on combined hormonal contraceptives:

• Testing can still be performed on modern low-dose formulations 2, 9
• Meta-analysis showed no significant difference in VWF% or FVIII% with COC use 9
• Discontinuation is not routinely required but consider if results are borderline

Bottom Line

Progesterone-only contraceptives do not interfere with VWD testing and should not be discontinued prior to diagnostic evaluation. The primary concern with hormonal contraceptives and VWF testing relates to estrogen-containing products, and even this effect appears minimal with modern low-dose formulations. Focus instead on avoiding testing during acute bleeding episodes and ensuring proper sample handling.